Abstract 117P
Background
PARP inhibitors are now the standard of care for patients with ovarian cancer. The determination of HRD status has become essential to predict sensitivity to these targeted therapies, and has to be integrated in routine oncology assays, beyond the search for BRCA1/2 pathogenic variants. We present the integration of an HRD assay based on tumor shallow whole genome sequencing (sWGS) fully integrated in an existing NGS workflow dedicated to somatic oncology.
Methods
25 samples from ovarian cancer with HRD status was determined using two CE-IVD assays (5 Sofia Genetics / 20 Myriad Genetics). Samples have been re-analysed, starting from FFPE blocks. We performed new DNA extractions from FFPE blocks followed by our dedicated workflow for solid tumor using NGS sequencing. DNA samples were prepared using hybridation method (Twist BioScience®) with Unique Molecular Identifiers (UMI). Part of libraries from HRD samples were collected before the capture step, and directly pooled for sequencing on Illumina® NextSeq 500. sWGS produced were analysed by a dedicated CE-IVD Bioinformatic pipeline for HRD status determination (SeqOne®).
Results
3 different runs of 10 samples each have been sequenced for replicability evaluation. No failure were encountered on any of the sequenced samples. The mean depth, Q30 quality and duplicate rates for sWGS produced were respectively 1.12X / 88.8% / 1.94%, far above the minimum requirements for analysis (> 0.1X). Replicability analysis show an average variation of 4% of the final HRD score. Regarding the HRD status determination, our results show an agreement of 93.3% with the status previously determined, in line with the results obtained by SeqOne during the validation of their bioinformatic analysis (93%).
Conclusions
Theses results demonstrate innovative integration into routine genetics’s laboratory. This implemented methodology allows us to provide a full report with both BRCA1/BRCA2 variant identification and the HRD status for each patient, in an efficient and cost-effective workflow.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
41P - HLA genotypes modify the age-related penetrance of BRCA1 pathogenic variants in breast cancer patients
Presenter: Ekaterina Kuligina
Session: Cocktail & Poster Display session
Resources:
Abstract
42P - Investigating the influence of extrachromosomal DNA in the progression of non-small cell lung cancer through the TRACERx and PEACE studies
Presenter: Jeanette Kittel
Session: Cocktail & Poster Display session
Resources:
Abstract
43P - MDM2 alterations in primary brain tumors: A potential niche for targeted therapy
Presenter: Diego Gomez Puerto
Session: Cocktail & Poster Display session
Resources:
Abstract
44P - Exploring miR-205 and miR-296 as salivary biomarkers and potential therapeutic targets in oral cancer
Presenter: Thaís Moré Milan
Session: Cocktail & Poster Display session
Resources:
Abstract
45P - Integrative analysis of TCGA DNA methylation, RNA-sequencing, and variant dataset using machine learning in predicting endometrial cancer recurrence
Presenter: Jinhwa Hong
Session: Cocktail & Poster Display session
Resources:
Abstract
46P - The role of microRNA-1246 in early detection of breast cancer: Findings from a systematic review and meta-analysis
Presenter: Muhammed Elfaituri
Session: Cocktail & Poster Display session
Resources:
Abstract
47P - Differential expression of discriminative markers in matched invasion fronts and tumour buds in CRC
Presenter: Laura Grech
Session: Cocktail & Poster Display session
Resources:
Abstract
48P - Transcriptome profiling highlights distinct gene signatures in HER2 high (HER2 3+) and HER 2 low (Her2 1+/2+) breast cancers
Presenter: Tamanna Thakur
Session: Cocktail & Poster Display session
Resources:
Abstract
49P - MiR-155 promotes breast cancer progression by upregulating cancer stemness
Presenter: Jeonghee Han
Session: Cocktail & Poster Display session
Resources:
Abstract
50P - Clinical impact of actionable molecular variants disclosed in late-stage cancer patients by tumor whole-exome sequencing in a prospective single-institution study
Presenter: Christophe Mapendano
Session: Cocktail & Poster Display session
Resources:
Abstract